Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.46 |
| ▸ | P4HB | P07237 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3329348 | 0.93 | SCN9A (0.41) | SCN9AP4HBALDH1A1GAAMAPT | |
| SCHEMBL3329230 | 0.91 | SCN9A (0.43) | SCN9AP4HBALDH1A1GAAMAPT | |
| SCHEMBL281989 | 0.89 | P4HB (0.40) | SCN9AP4HBALDH1A1TSHRGAA | |
| SCHEMBL15314997 | 0.88 | SCN9A (0.45) | SCN9AALDH1A1TSHRGAAUSP2 | |
| SCHEMBL281952 | 0.85 | SCN9A (0.35) | SCN9AP4HBALDH1A1GAAMAPT | |
| SCHEMBL281180 | 0.85 | SCN9A (0.35) | SCN9AALDH1A1GAAMAPT | |
| SCHEMBL281242 | 0.84 | SMN1; SMN2 (0.36) | SCN9AP4HBALDH1A1TSHRGAA | |
| SCHEMBL15312872 | 0.84 | SCN9A (0.47) | SCN9AP4HBALDH1A1TSHRGAA | |
| SCHEMBL281473 | 0.84 | SCN9A (0.47) | SCN9AP4HBALDH1A1TSHRGAA | |
| SCHEMBL3329674 | 0.83 | SCN9A (0.39) | SCN9AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101213174-A | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2008-07-02 | — | — | CN | claimed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | claimed |
| EP-2838902-B1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2018-12-05 | — | — | EP | disclosed |
| EP-3241834-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2017-11-08 | — | — | EP | disclosed |
| US-20170066777-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-03-09 | — | — | US | disclosed |
| US-9487535-B2 | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-08 | — | — | US | disclosed |
| US-9487535-B2 | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-08 | — | — | US | disclosed |
| US-9487535-B2 | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-11-08 | — | — | US | disclosed |
| EP-2838902-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2015-02-25 | — | — | EP | disclosed |
| EP-2428515-B9 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2014-09-17 | — | — | EP | disclosed |
| EP-2752417-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2014-07-09 | — | — | EP | disclosed |
| CN-101213174-A | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2008-07-02 | — | — | CN | disclosed |
| WO-2008060789-A2 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008046083-A2 | USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| EP-1888595-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-02-20 | — | — | EP | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
| WO-2006110917-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | SCN9A 148/4885P4HB 3675/4885ALDH1A1 1136/4885 |
| US-20170066777-A1 | ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS | OPRK1, OPRL1, PKD2 | SCN9A 51/4885P4HB 3458/4885ALDH1A1 712/4885 |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | OPRK1, OPRD1, SCN3A | SCN9A 47/4885P4HB 1566/4885ALDH1A1 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.